The list compiled by Alantra, an international financial services company, ranks companies according to their revenue growth over the past two years.

Richmond Pharmacology is delighted with the recognition and features in the lists top twenty at number 17. The Alantra Pharma Fast 50 is in its fifth year and was launched to recognise and celebrate successful business within the UK life sciences market.

The list includes analysis of businesses grouped into four distinct sub-sectors – Technology; Analytics, insights and communication; Pharma outsourcing; and Develop, wholesale and supply.

Richmond Pharmacology is categorised in the publication as a Contract research organisation providing services from design to delivery of early phase clinical trials.

Read the report in full

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event